Compare GSK plc (GSK) vs Halliburton Company (HAL) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Halliburton (HAL) trades at $34.99, down 1.21% on the day, with a bullish technical signal from moving averages and recent contract wins boosting sentiment. The company shows solid profitability with a 6.95% net income margin and 14.56% ROE, though 2025 revenue dipped to $22.18B. Earnings have beaten estimates for three consecutive quarters, with Q2 2026 results pending. Cash flow trends are mixed, with 2025 net cash flow negative at -$412M despite strong operational cash generation.

The outlook remains positive with a consensus price target of $44.78, implying 28% upside, supported by 71% analyst buy ratings. Key risks include oil price volatility and execution challenges from new contracts. The stock's current valuation at a P/E of 19.48 appears reasonable relative to growth prospects, but investors should monitor debt levels and global energy demand shifts.